Generalized resistance to thyroid hormone (GRTH) is a syndrome of hyposensitivity to triiodothyronine (T3) that displays autosomal dominant inheritance. 
Introduction
Generalized resistance to thyroid hormone (GRTH)' is a syndrome characterized by elevated circulating levels ofthyroxine (T4) and triiodothyronine (T3) with inappropriately normal or increased levels of thyroid-stimulating hormone ( 1, 2) . Pa-tients with this syndrome have partial refractoriness to the effects ofthyroid hormone, which is variable in individual target tissues. Furthermore, the clinical phenotypes are different among affected families (2, 3) . The pattern of inheritance of GRTH is autosomal dominant in the majority of cases (2, 3) , although the occurrence of autosomal recessive transmission has been documented in one family (4) .
Although thyroid hormone receptor (TR) mutations had been suspected based on decreased thyroid hormone binding in fibroblasts of affected patients (3, 5) , direct demonstration of TR mutations could not be undertaken until cDNAs encoding TRs had been identified. Recently, two different thyroid hormone receptor genes, hTRa and hTR46, that encode highly homologous DNA-binding proteins that bind T3 have been identified in humans (6) (7) (8) . The TRs are members ofa large superfamily of receptors, including the estrogen, glucocorticoid, vitamin D, and retinoic acid receptors (9, 10) . In common with other members, they have several domains, including a central DNA-binding domain containing two "zinc fingers" and a carboxyl-terminal ligand-binding domain.
Recent studies of subjects with GRTH have identified single amino acid substitutions in the ligand-binding domain of their TR3-I ( I 1-15). In the first two families described, the mutant TRW-I had either glycine 345 replaced by arginine (Mf-1) or proline 453 replaced by histidine (I 1, 12) . Mutations in all families with GRTH so far characterized cluster near those described in these two families ( 15, 16) . Affected members of these families have one normal and one abnormal TR#I allele, consistent with the autosomal dominant mode of inheritance predicted by pedigree analysis. In vitro transcription and translation of the mutant receptors in some of the families showed either reduced or virtually absent T3-binding affinity ( 13, 16, 17) . Transient transfection assays using two ofthe TRf3-1 point mutants (including Mf-1 ) have shown that they not only fail to mediate normal T3-regulated transcription but also can block the T3-regulated transcription by normal TRs (18, 19) . The mechanism of this dominant negative effect of the mutant TR3-1 allele on the normal TRJ3 and TRa-1 isoforms is open to speculation. It has been hypothesized that the mutant TRI3-1 can dimerize with normal TRs interfering with their ability to mediate ligand-regulated transcription (18) (19) (20) (31) (32) (33) (34) (35) . RXRs are members of the same superfamily ofreceptors as TRs and bind to a putative endogenous ligand, 9-cis retinoic acid (36) . Recently, T3 has been shown to have no effect on TR/RXR heterodimer binding to TREs (36a). (6, 28, 30, 37, 38 (26, 39) and by SDS-PAGE analysis of [35S] methioninelabeled receptors that showed labeled proteins of expected molecular weights.
Preparation ofnuclear extracts. Nuclear extract from the rat pituitary lactotropic cell line 235-1 was prepared and stored as previously described (26) . These 
Results
We first examined the binding of native human TR#-l and Mf-1 to a labeled oligonucleotide containing the chick lysozyme gene TRE (F2) by using EMSA. As previously shown with TRB-1 (25) , Mf-l bound almost exclusively as a homodimer on this TRE ( Fig. 1 A) (Fig. 1 A) , as reported previously (25) . In contrast, T3 did not decrease Mf-1 homodimer binding to F2 unless much higher concentrations of T3 were added (EC50 of -1.0 X 10-6 M) ( Fig. 1 A and B) . This diminished T3 effect on Mf-1 DNA-binding is consistent with the minimal T3 binding previously reported for in vitrotranslated Mf-I ( 18, 19). We next examined whether Mf-1 could form heterodimers with TRAP on two different TREs, F2 and DR4 (a synthetic, positively regulated TRE in which half-sites are oriented as direct repeats and separated by a gap offour nucleotides) (41 ) . and Mf-l. TR#-1 formed heterodimers preferentially over homodimers on these TREs. As previously reported, when T3 was added to TR#-1 and nuclear extract, homodimer no longer bound to DNA but heterodimer remained bound to F2. In contrast, both Mf-l and Mf-l /TRAP heterodimer remained bound to F2 in the presence of 10-7 M T3 (data not shown).
We also examined whether these receptors could form heterodimers with RXRB, a member of the steroid hormone receptor/TR superfamily that binds to the MHC Class I gene regulatory region and fl-retinoic acid receptor gene (28, 29, 35 and DR4 (Fig. 4, lanes 3 , 6, and 9) that were stable after T3 addition (data not shown). Also, the receptor/TRAP heterodimer band migrated more slowly than the receptor/RXRI3 heterodimer band, suggesting that TRAP in the pituitary may be different than RXR,3 (Fig. 4, lanes 3, 4, 6 , 7, 9, and 10).
To examine whether the mutant receptor could exert its dominant negative effect via direct interaction with other TR isoforms, we compared the formation ofTRa-I /TR3-I dimers with TRa-1 /Mf-l dimers and the effect ofT3 on DNA-binding by these dimers. We previously showed that incubating TRac-l and TR#-l together produced TRa-1 /TR3-1 dimers bound to F2 and addition of T3 decreased DNA-binding of these dimers (25) . When TRa-1 and Mf-1 were incubated together, there was loss of TRa-1 homodimer band and formation of a new large band composed of mostly TRa-l /Mf-l dimers (faster migrating) and a small amount of residual Mf-l homodimers (slower migrating) (Fig. 5, lane 7) . The presence of TRa-I/ Mf-l dimers was confirmed by coincubation with anti-TRa and TRj#-I isoform-specific antibodies (42) in the DNA-binding reaction and observation of appropriate supershifts (data not shown). When IO-7 M T3 was added to the DNA-binding reactions, T3 abolished TRa-I/Mf-l dimer but not Mf-l homodimer binding to F2 (Fig. 5, lane 9) . Only when 10-6 M T3 was added did Mf-homodimer dissociate from F2 (Fig. 5,  lane 8 ). These data demonstrate that TRa-1 /Mf-1 dimer behaves similarly to TRa-I /TRj-1 dimer, as it is more sensitive to the T3-mediated decrease in homodimer binding to F2 than the Mf-l homodimer. Moreover, these data suggest that T3 only needs to bind to TRa-l for the TRa-l/Mf-l dimer to dissociate from F2 since Mf-l most likely does not bind T3 at l0-7 M ( 18, 19) and therefore does not affect Mf-l homodimer binding to DNA at this concentration (Fig. 1 ). We next compared the formation of TR3-1 homodimer with Mf-1 /TR,3-1 dimer since direct interaction ofthe mutant receptor with wild-type TR,#-I receptor could account for its dominant negative effect. To demonstrate Mf-1 /TRI-I dimer binding we used a mutant rat TR#-I, AN, in which amino acids 71 -100 were deleted from the amino-terminal end ofthe receptor (28) . The epitopes for the anti-TRB-1 antibody are contained within this deleted region since the synthetic peptide used to generate the antibody was derived from amino acids 73-93. Therefore, when AN was mixed with either Mf-1 or TRB-1, we expected the antibody to supershift Mf-1 and TRfl-1 homodimers as well as receptor/AN dimers, but not AN homodimers, thereby confirming the formation of any receptor/ AN dimers. AN bound weakly as a homodimer with similar mobility as TR43-I and dissociated from F2 after the addition of l0-7 M T3. (Fig. 6 A, lanes 4 and 5) . When it was mixed with TR,3-1, an intense band was observed in the region of the homodimer (Fig. 6 A, lane 6) , which likely represented TR#-1 homodimers and new TRB-1/AN dimers as these complexes were supershifted with anti-TRB-1 antibody (Fig. 6 C, lanes I  and 2) . Similar results were seen when AN was mixed with Mf-l (Fig. 6 B and C) . When l0-7 M T3 was added to the DNA-binding reactions containing TR,8-1 and AN, all the dimer binding was abolished as expected since both TR#-I and AN homodimers dissociated from F2 at this T3 concentration (Fig. 6 A, lane 7) . However, similar to the case ofTRac-1 /Mf-l dimers, l0-7 M T3 decreased most ofthe intensity ofthe large band representing mainly Mf-1/AN dimers (Fig. 6 B, lanes 7  and 10) . The small amount of residual bound complexes ob- (45, 46) . We previously have proposed that T3-induced dissociation of homodimers from TREs may be necessary to remove repression before ligand-bound heterodimer can regulate transcription (25) . Ifthis is the case, it is conceivable that a mutant receptor that binds very poorly to T3, when bound as a homodimer to a TRE, may maintain a target gene in a tonically repressed state. Increased expression or stability of the mutant TR, as well as increased binding to some TREs, may further augment this repressive ability ofthe mutant TR. Another possible mechanism for a mutant receptor to decrease sensitivity to T3 is based on our previous observation that ligand-bound TR/TRAP heterodimer is the only receptor complex that remains bound to several TREs in the presence of T3 (25) . This, in turn, suggests that the TR/TRAP heterodimer may be the functionally relevant receptor form in T3-mediated transcription for some genes (25) . Since Mf-1 binds poorly to T3, the Mf-1/TRAP heterodimer would not be expected to mediate ligand-regulated transcription by this mechanism. Thus, formation of mutant TR/ nuclear protein heterodimers may have a dominant negative effect either by titrating limiting amounts of auxiliary proteins or coactivators (squelching) or by competing with wild-type TR/nuclear protein heterodimers for binding to TREs. In a given cell, alterations in the expression of Mf-or the stability of Mf-l /TRAP heterodimers compared with normal TR/TRAP heterodimers could affect the population of abnormal heterodimers and thereby determine the amount of T3 resistance in the cell.
On the basis of our data, we propose that the dominant negative effect by Mf-l and the decreased sensitivity to T3 within the cells ofthe patients with this mutation are not due to abnormal interactions with TRac-l and TR,3-I by Mf-l. Instead, they likely occur by one or both ofthe following mechanisms: repression by mutant homodimers that bind to TREs but do not dissociate from the TREs in the presence of T3 and/or diminished ligand-regulated transcription by Mf-l / TRAP heterodimers since Mf-binds poorly to T3. The possibility of multiple regulatory steps that might affect these two mechanisms and differences in impairment of T3 binding among the different TRj-1 mutations observed in kindreds with GRTH may account for the variability in tissue resistance to T3 in affected patients as well as the differences in phenotypes among kindreds with this syndrome.
